Inverness Counsel’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-3,035
Closed -$212K 195
2021
Q3
$212K Buy
+3,035
New +$213K 0.01% 169
2020
Q3
Sell
-2,716
Closed -$209K 138
2020
Q2
$209K Buy
+2,716
New +$208K 0.01% 117
2017
Q2
Sell
-3,204
Closed -$212K 94
2017
Q1
$212K Sell
3,204
-2,705
-46% -$190K 0.01% 88
2016
Q4
$430K Sell
5,909
-35,030
-86% -$2.6M 0.03% 77
2016
Q3
$3.24M Sell
40,939
-87,759
-68% -$7.13M 0.25% 49
2016
Q2
$10.7M Sell
128,698
-180,330
-58% -$16M 0.83% 39
2016
Q1
$28.4M Buy
309,028
+3,407
+1% +$307K 2.2% 16
2015
Q4
$30.9M Buy
305,621
+16,570
+6% +$1.72M 2.34% 12
2015
Q3
$28.4M Buy
289,051
+58,373
+25% +$6.48M 2.4% 10
2015
Q2
$27M Sell
230,678
-11,170
-5% -$1.22M 1.96% 16
2015
Q1
$23.7M Sell
241,848
-41,770
-15% -$4.24M 1.75% 21
2014
Q4
$26.7M Sell
283,618
-70,056
-20% -$7.25M 2.05% 16
2014
Q3
$37.6M Sell
353,674
-46,956
-12% -$4.6M 3.02% 5
2014
Q2
$33.2M Sell
400,630
-74,641
-16% -$5.81M 2.59% 8
2014
Q1
$33.7M Sell
475,271
-170,340
-26% -$13.4M 2.68% 6
2013
Q4
$48.5M Sell
645,611
-14,204
-2% -$989K 3.85% 4
2013
Q3
$41.5M Sell
659,815
-29,773
-4% -$1.78M 3.56% 4
2013
Q2
$35.4M Buy
+689,588
New +$35.9M 3.15% 4

Other funds holding GILD

Inverness Counsel's GILD Position: Q4 2021 in Review

Inverness Counsel sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 3,035 shares — an estimated $212K sold.

Inverness Counsel first reported a position in GILD in Q2 2013 and held it in 18 quarters. The position peaked at $48.5M in Q4 2013. 1,683 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

  • Inverness Counsel reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
  • Inverness Counsel sold 3,035 Gilead Sciences shares in Q4 2021, an estimated $212K.
  • Inverness Counsel first reported a position in Gilead Sciences in Q2 2013 and held it in 18 quarters.
  • Inverness Counsel's Gilead Sciences position peaked at $48.5M in Q4 2013.
  • 1,683 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on Inverness Counsel's 13F filing for Q4 2021, filed 7 Feb 2022.